The Edit Review: $209/mo, and the $109 Catch

The Edit (theedithealth.com) advertises semaglutide at $109 and tirzepatide at $209. Neither number is what you will pay in month two. Both are a $100-off first-order promotion, and the standing rate underneath is $209 and $309. We checked the whole ladder in August 2026, ran the arithmetic on every prepay rung, and found something unusual: the pricing is completely honest apart from that headline. It is also, on this board, expensive.

The real ladder

Month to month, semaglutide is $209 and tirzepatide is $309. Prepay and the per-month figure drops: $575 once for three months of semaglutide, $1,065 once for six; $855 once for three months of tirzepatide, $1,575 once for six.¹

Those prepay rungs are labelled "billed once at the start of the plan", which is the labelling most operators skip, and the per-month figures the site prints beside them divide correctly — $575 over three months is $192, $1,065 over six is $178, $855 over three is $285, $1,575 over six is $263. We check that division on every provider because it is where the padding usually hides. Here there is none.

What six months actually costs

Take semaglutide. Paying month to month, six months is $1,254. Buying the six-month plan up front is $1,065 — a difference of $189, and you are committed. Tirzepatide runs $1,854 month to month against $1,575 prepaid, a difference of $279.

That is a real discount for a real commitment, and it is small enough to be worth refusing if you are not certain you will stay on treatment. The teaser-rate playbook is worth reading against this page specifically: the $100-off headline does exactly what a teaser does — it wins the click at a number that appears once — but the rest of the structure does none of the things a teaser structure does. There is no step-up, no minimum term, and no hidden month-two rate. The recurring price is printed on the same page as the promo.

Where it lands on price

$209 a month for compounded semaglutide is upper-quartile. We are a savings desk and we are not going to pretend otherwise: several programs on the semaglutide price ladder beat it outright, and two providers we reviewed in the same batch — Pepti at $99 flat and Trellis Vitality at $150 month to month — undercut it by $59 to $110 a month with published ladders of their own. Over six months that is a $354 to $660 gap. The Edit's case is not price. It is that everything it publishes about price turns out to be true.

Who is actually behind it

The medical group is Arora Health & Aesthetics, LLC, medical director Dr. Sean Arora, NPI 1841729449 — active in the federal NPPES registry, Family Medicine, licensed in New Hampshire, Michigan and Washington.² The dispensing pharmacy is named: The Pharmacy Hub, inside what the site calls The Edit Health Pharmacy Network. A named pharmacy plus a verifiable prescriber NPI puts this provider ahead of most of the market, and well ahead of the three programs in this batch that name neither. If you are not sure why that matters, how to verify a compounding pharmacy is legitimate is the checklist.

One thing to hold onto: Trellis Vitality uses the same medical group and the same medical director. Different pharmacies, different prices, separable products — but they are not two independent clinical opinions. If you are shortlisting both as alternatives to each other, you are shortlisting one clinical operation twice.

The corporate entity is The Edit Health LLC, a Texas management services organisation at 5900 Balcones Drive, Austin. It also operates a second domain, startyouredit.com.

The rest of the shelf, and the parts that are free

Beyond the two GLP-1 protocols: NAD+ at $249 a month, glutathione at $199, sermorelin at $169 and GHK-Cu cream at $129.¹ All injectable except the cream. The site states plainly that it does not sell research-use-only compounds, and the catalogue backs that up — no retatrutide, no oral GLP-1, no nasal line.

Starting is genuinely free: no charge and no card on file to begin, and a full refund if you are not approved. Once a visit has occurred the visit fee is non-refundable, but no visit fee is charged up front. Prescriptions are final sale, which is standard for compounded medication. Membership cancels at the end of the current period with no proration, under a cancellation policy dated July 2026. All 50 states, with address-level eligibility confirmed during the consultation.

It also ships a complete Spanish mirror — 33 Spanish URLs, every page. That is rare enough in this market to be worth naming.

The regulatory screen

We ran the trading name, the legal entity, the medical group and the named pharmacy against the FDA's live warning-letter index in August 2026. Zero company-column matches on all four.³ The same pass carried a positive control — an unrelated telehealth seller with a real February 2026 letter — which returned correctly every time, so the zeros are evidence rather than a query that failed quietly.

The verdict for a bargain hunter

Ignore the $109. Budget $209 a month, or $1,065 for six months if you are sure. What you are buying at that price is a named pharmacy, a checkable prescriber, arithmetic that survives being checked, and a Spanish site if you need one. What you are not buying is a low price. If price is the binding constraint, start from how to choose a GLP-1 provider without overpaying and work down the ladder; if verification is the binding constraint, this is one of the few programs in the batch that clears it. The rest of what we publish sits in the research library.